AI Summary In a clinical trial, weekly semaglutide resolved steatohepatitis in 62.9% of MASH patients with fibrosis, versus 34.3% on placebo, according to the Liver Therapies Patient Guide.
Medically reviewed.
GLP-1 / incretin-based therapy is a group of medications originally developed for type 2 diabetes and weight management that mimic natural gut hormones called incretins. By slowing digestion, reducing appetite, and improving how the body uses insulin, these medications support weight loss and metabolic health — and are now being studied for their emerging role in managing MASLD (metabolic dysfunction-associated steatotic liver disease) and MASH (metabolic dysfunction-associated steatohepatitis).
This page explains how GLP-1/incretin-based therapies work, who may benefit, and what the evidence shows about their effect on liver fat, inflammation, and fibrosis. You can also connect with a liver specialist to discuss whether one of these therapies fits your care plan.
Liver Health AI Assistant
Ask Aimy
Aimy answers from LiverDirectory’s reviewed health information — helping patients make sense of liver-health terms, prepare for specialist visits, and explore what to look up next.
GLP-1 / INCRETIN-BASED THERAPY OVERVIEW
GLP-1/incretin-based therapies are a class of medications that mimic gut hormones called incretins, which help regulate blood sugar, appetite, and digestion. Semaglutide-based medicines act on the GLP-1 receptor alone, while tirzepatide activates both the GIP and GLP-1 receptors. Care built around these medications typically combines the drug with lifestyle changes and regular monitoring, and treatment plans are personalized based on a person's diagnosis, overall health, and individual needs.
You can explore the individual GLP-1/incretin-based therapies below and learn how they may support weight loss, metabolic health, and — in some cases — liver fat and fibrosis improvement. Because eligibility depends on your specific diagnosis and health history, connecting with a liver specialist can help you understand which option fits your care plan.
Semaglutide is a GLP-1 receptor agonist available as a weekly injection (Ozempic, Wegovy) or a daily pill (Rybelsus). It slows stomach emptying, reduces appetite, and helps the body use insulin more effectively. In a clinical trial of adults with MASH and moderate to advanced fibrosis, semaglutide resolved steatohepatitis in 62.9% of treated patients, compared with 34.3% on placebo.
Explore semaglutide therapies:
Tirzepatide is a dual GIP and GLP-1 receptor agonist, mimicking two natural hormones that regulate blood sugar, appetite, and metabolism. Mounjaro is approved for type 2 diabetes, and Zepbound for chronic weight management. Both support significant, sustained weight loss when combined with diet and exercise.
Explore tirzepatide therapies:
Liraglutide is a daily-injection GLP-1 receptor agonist. Victoza is approved for type 2 diabetes and cardiovascular risk reduction, while Saxenda uses a higher dose for chronic weight management. In the LEAN trial, liraglutide showed benefit for resolving nonalcoholic steatohepatitis compared with placebo.
Explore liraglutide therapies:
Healthcare providers may consider GLP-1/incretin-based therapy for adults with type 2 diabetes, obesity, or overweight with a weight-related condition, especially when diet and exercise alone have not achieved adequate blood sugar control or weight loss. These medications are also gaining an emerging role for people with MASLD or MASH who have overlapping metabolic risk factors.
DIET & LIFESTYLE SUPPORT
GLP-1/incretin-based therapy works best when combined with lifestyle changes. Nutrition, physical activity, weight management, and control of related metabolic conditions all support the benefits these medications can offer for blood sugar, weight, and liver health.
A calorie-appropriate, liver-friendly diet supports the appetite and calorie-intake changes that GLP-1 medications help create, and may add to their effect on liver fat.
Managing related conditions such as diabetes, high cholesterol, and high blood pressure remains an essential part of care alongside medication.
Regular physical activity supports metabolic health and works alongside medication to help manage weight and blood sugar.
A nutrition bar designed for liver health can be a simple, consistent way to help meet daily energy and protein goals alongside medication.
Explore Liver Health Nutrition Bars
GLP-1 THERAPY AND METABOLIC LIVER DISEASE
GLP-1/incretin-based therapies were first developed for type 2 diabetes and weight management, and researchers are now studying their emerging role in MASLD and MASH. AASLD guidelines list GLP-1 receptor agonists such as semaglutide among the emerging therapies being evaluated for liver disease, noting their effect on weight and hepatic inflammation alongside other options such as the THR-β agonist resmetirom.
Because liver fat, inflammation, and fibrosis often improve alongside weight loss and better blood sugar control, these medications are increasingly considered as part of metabolic liver disease care. Still, no GLP-1/incretin medication currently carries an FDA approval specifically for MASLD or MASH — the evidence below reflects clinical trial results rather than an approved liver-disease indication.
In a trial of adults with biopsy-confirmed MASH and moderate to advanced fibrosis, weekly semaglutide resolved steatohepatitis in 62.9% of treated patients without worsening fibrosis, compared with 34.3% on placebo, and reduced fibrosis by at least one stage in 36.8% of patients.
Alongside liver improvements, semaglutide-treated patients lost an average of about 10.5% of body weight in clinical trials — losses in the range shown to reduce liver fat and inflammation.
The LEAN trial found that liraglutide helped resolve nonalcoholic steatohepatitis (now called MASH) more often than placebo, supporting an early role for GLP-1 therapy in liver-focused care.
No GLP-1/incretin medication currently carries an FDA approval specifically for MASLD or MASH; approvals are for type 2 diabetes or weight management. Your healthcare provider weighs the liver-related evidence alongside your diagnosis when deciding if this therapy fits your plan.
TREATMENT MONITORING
Regular monitoring helps your healthcare provider evaluate how your body is responding to GLP-1/incretin-based therapy and track any liver-related changes over time. Follow-up care may include blood tests, imaging, and fibrosis assessments alongside routine diabetes or weight-management monitoring.
Liver function tests track enzymes and other markers that show how your liver is responding to treatment and help flag any changes early.
Providers use metabolic markers alongside liver tests to track blood sugar, liver fat, and related risk factors over time.
Imaging and, in selected cases, biopsy can assess liver fat and fibrosis directly and help guide treatment decisions during long-term therapy.
Only a qualified healthcare provider can adjust your treatment plan based on your test results and health history.
COMMON QUESTIONS
GLP-1/incretin-based therapy is a class of medications originally developed for type 2 diabetes and weight management, including semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound), and liraglutide (Victoza, Saxenda). They mimic natural gut hormones to help regulate blood sugar, appetite, and digestion. These medications are also gaining an emerging role in managing MASLD and MASH because of their effects on weight and liver fat. Talk with your healthcare provider about whether this therapy fits your treatment plan.
These medications mimic incretin hormones that the gut releases after eating. They slow stomach emptying, stimulate insulin release when blood sugar is high, reduce the amount of glucose the liver releases, and reduce appetite. Tirzepatide additionally activates the GIP receptor for added metabolic effect. Together, these actions support blood sugar control and weight loss, which can also reduce liver fat and inflammation.
Healthcare providers typically consider these medications for adults with type 2 diabetes, or with obesity or overweight and at least one weight-related condition, especially when diet and exercise alone have not achieved adequate control. People with MASLD or MASH who have overlapping metabolic risk factors may also be considered, since evidence shows liver benefits alongside weight and blood sugar improvement. Eligibility depends on your specific diagnosis and health history.
In a clinical trial of adults with biopsy-confirmed MASH and moderate to advanced fibrosis, weekly semaglutide resolved steatohepatitis in 62.9% of treated patients without worsening fibrosis, compared with 34.3% on placebo, and reduced fibrosis by at least one stage in 36.8% of patients. Treated patients also lost an average of about 10.5% of body weight. Results vary by individual, so discuss your specific expectations with your healthcare provider.
The most common side effects across this class are gastrointestinal — nausea, vomiting, diarrhea, or constipation — which are usually mild to moderate and often improve over time. Other reported effects include stomach discomfort or bloating, decreased appetite, headache, fatigue, and occasional injection site reactions. Your healthcare provider will monitor you regularly and can help manage any side effects that arise.
No, GLP-1/incretin-based therapy works alongside lifestyle changes rather than replacing them. A liver-friendly diet, regular physical activity, weight management, and control of related conditions like diabetes and high cholesterol remain essential parts of care. These medications can support weight loss and metabolic health, but they work best when combined with these ongoing habits. Ask your healthcare provider how to build a plan that pairs medication with lifestyle support.
No, not currently. Semaglutide, tirzepatide, and liraglutide are FDA-approved for type 2 diabetes or chronic weight management, not specifically for MASLD or MASH. Clinical trial evidence shows liver-related benefits — including improvements in steatohepatitis and fibrosis — but a liver-specific approval has not been granted for this drug class. Your healthcare provider can explain how the evidence applies to your diagnosis.
Medical disclaimer: LiverDirectory provides educational information and a directory of providers. It does not provide medical advice, diagnosis, or treatment. Always consult a licensed physician regarding any medical condition.
